Affimed to end cancer program and focus on innate immunity portfolio, shares slide about 10% - MarketWatch

in dlike •  6 years ago 

Shared From Dlike

Clinical stage biotech Affimed N.V. said Wednesday it is terminating its phase I program for AFM11 to focus on its innate immunity portfolio. The company had...


Source of shared Link

dlike dlike-news
6 years ago by

Downvoting a post can decrease pending rewards and make it less visible. Common reasons:

  • Disagreement on rewards
  • Fraud or plagiarism
  • Hate speech or trolling
  • Miscategorized content or spam

Submit
$0.00
  • Max accepted payout: $900.00
3 votes
0
Authors get paid when people like you upvote their post.
If you enjoyed what you read here, create your account today and start earning FREE STEEM!